PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
-0.69
Both companies show negative D/E. Martin Whitman would investigate if industry distress creates special situation opportunities.
2.47
Net debt while CRVO maintains net cash position. John Neff would demand higher returns to justify the additional leverage risk.
-1.27
Both companies show negative coverage. Martin Whitman would investigate if industry distress creates special situation opportunities.
0.01
Current ratio 50-75% of CRVO's 0.01. Bill Ackman would demand clear path to liquidity improvement.
No Data
No Data available this quarter, please select a different quarter.